Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Renal Drug Excretion: Overview

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules out...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Variability in Cardiac Stress Test Interpretation: Agreement Between Enrollment Sites and Core Laboratories in the Global ISCHEMIA Trial.

Circulation. Population health and outcomes·2026

Same author

How Ambient AI Could Bring the Human Touch Back to Medicine.

Missouri medicine·2026

Same author

Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 34 Trials including 114,326 Individuals.

medRxiv : the preprint server for health sciences·2025

Same author

Associations Between Plasma Omega-3 and Fish Oil Use With Risk of Atrial Fibrillation in the UK Biobank.

Journal of the American Heart Association·2025

Same author

The association between plasma omega-3 fatty acids and suicidal ideation/self-harm in the United Kingdom Biobank.

Lipids in health and disease·2025

Same author

A review of the relationships between reported fish oil supplement use and health outcomes in the UK Biobank.

Prostaglandins, leukotrienes, and essential fatty acids·2025

Search research articles

Related Experiment Videos

Review article: eplerenone: an underused medication?

Mohammad Abuannadi¹, James H O'Keefe

¹Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, USA.

Journal of Cardiovascular Pharmacology and Therapeutics

|September 30, 2010

Summary

This summary is machine-generated.

Eplerenone, an aldosterone antagonist, improves cardiovascular outcomes in patients with heart failure and hypertension. It offers benefits similar to spironolactone but with fewer sexual side effects, though hyperkalemia risk requires monitoring.

Related Experiment Videos

Area of Science:

Cardiovascular Medicine
Pharmacology

Background:

The renin-angiotensin-aldosterone system is implicated in heart disease pathogenesis.
Aldosterone antagonists like spironolactone and eplerenone offer prognostic benefits.

Purpose of the Study:

To review evidence for eplerenone in improving cardiovascular prognosis.
To evaluate eplerenone's efficacy in hypertension and heart failure.

Main Methods:

Review of clinical evidence and trials.
Analysis of eplerenone's effects on cardiovascular outcomes, remodeling, and risk markers.

Main Results:

Eplerenone improves outcomes in myocardial infarction with LV dysfunction and heart failure.
Eplerenone treats hypertension, reducing left ventricular hypertrophy and proteinuria.
Eplerenone has fewer sexual side effects than spironolactone.

Conclusions:

Eplerenone provides aldosterone antagonism benefits with a better side effect profile than spironolactone.
Careful patient selection and monitoring are crucial due to hyperkalemia risk.